Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study

Ruxolitinib, a potent Janus kinase 1/2 inhibitor, has demonstrated durable improvements in patients with myelofibrosis. In this analysis of the Phase 3b JUMP study, which included patients aged ≥18 years with a diagnosis of primary or secondary myelofibrosis, we assessed the safety and efficacy of r...

Descripción completa

Detalles Bibliográficos
Autores principales: Passamonti, Francesco, Gupta, Vikas, Martino, Bruno, Foltz, Lynda, Zaritskey, Andrey, Al‐Ali, Haifa Kathrin, Tavares, Renato, Maffioli, Margherita, Raanani, Pia, Giraldo, Pilar, Griesshammer, Martin, Guglielmelli, Paola, Bouard, Catherine, Paley, Carole, Tiwari, Ranjan, Vannucchi, Alessandro M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518822/
https://www.ncbi.nlm.nih.gov/pubmed/34224180
http://dx.doi.org/10.1002/hon.2898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518822/
https://www.ncbi.nlm.nih.gov/pubmed/34224180
http://dx.doi.org/10.1002/hon.2898

Ejemplares similares